RxDoctor Payments Data

Adam Deutsch, MD

Cardiovascular Disease · New York, NYNPI 1275532533

Payments from drug & device makers

$1,909in general payments, 2019–2025

Across 95 payments — averaging $20.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$355
  • Amgen$352
  • Kowa Pharmaceuticals America, Inc.$136
  • Merck$110
  • Johnson & Johnson$107
  • Kiniksa Pharmaceuticals International, PLC$106
  • plus $743 from 15 others

What the payments were for

  • Food & beverage$1,88799%
  • Education$221%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,909 in reported general payments places this provider in the 50th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$817,364
Medicare patients
621
Services billed
6,792

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban145$189,157
Repatha SureclickEvolocumab75$81,441
XareltoRivaroxaban59$67,428
EntrestoSacubitril/Valsartan51$65,384
FarxigaDapagliflozin Propanediol25$21,830
Praluent PenAlirocumab13$11,977
Rosuvastatin Calcium550$10,978
Ezetimibe132$4,300
Ranolazine ErRanolazine21$3,614
Losartan Potassium349$3,448
Atorvastatin Calcium248$3,319
Metoprolol Succinate202$3,116
Amlodipine Besylate286$2,401
Alcohol PadsAlcohol Antiseptic Pads11$1,666
Metoprolol Tartrate139$1,171

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$89$189,157145 claims
Johnson & JohnsonXarelto$107$67,42859 claims
NovartisEntresto$355$65,38451 claims
AstraZenecaFarxiga$86$21,83025 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →